There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Nemaura Medical (NMRD – Research Report), Atreca (BCEL – Research Report) and Arcellx Inc (ACLX – Research Report) with bullish sentiments.
Nemaura Medical (NMRD)
In a report released today, Constantine Davides from EF Hutton reiterated a Buy rating on Nemaura Medical, with a price target of $6.00. The company’s shares closed last Wednesday at $0.90.
According to TipRanks.com, Davides ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Nemaura Medical with a $6.50 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Atreca (BCEL)
EF Hutton analyst Anthony Butler reiterated a Buy rating on Atreca today and set a price target of $10.00. The company’s shares closed last Wednesday at $1.30, close to its 52-week low of $0.76.
According to TipRanks.com, Butler is a 3-star analyst with an average return of
Atreca has an analyst consensus of Moderate Buy, with a price target consensus of $12.17, representing a 914.2% upside. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $25.00 price target.
Arcellx Inc (ACLX)
SVB Securities analyst Daina Graybosch maintained a Buy rating on Arcellx Inc today and set a price target of $39.00. The company’s shares closed last Wednesday at $31.09, close to its 52-week high of $35.16.
According to TipRanks.com, Graybosch is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on Arcellx Inc is a Strong Buy with an average price target of $39.25, implying a 29.0% upside from current levels. In a report released today, H.C. Wainwright also assigned a Buy rating to the stock with a $40.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on NMRD:
- Nemaura Medical participates in a conference call with EF Hutton
- Nemaura includes insulin on list of drugs eligible for EU DuoPack license
- Nemaura Includes Insulin on List of Drugs Eligible for EU DuoPack License Agreement
- Nemaura Medical Announces Receipt of Notice from Nasdaq
- Nemaura Medical receives Nasdaq noncompliance notice
